vTv Therapeutics (FRA:5VT0) Tariff Resilience Score: 8/10 (As of Jul. 04, 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €30.20
GF Value €6,725.03
View Full Analysis

What is vTv Therapeutics Tariff Resilience Score?

vTv Therapeutics FRA:5VT0 +0.67% 35 Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,725.03. Among 1,373 Biotechnology companies, vTv Therapeutics ranks better than 98.69% on this metric.

vTv Therapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

vTv Therapeutics has vTv Therapeutics has low tariff exposure as it primarily operates in the U.S. with minimal international supply chain dependencies. The pharmaceutical industry often benefits from tariff exemptions, reducing potential impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes vTv Therapeutics might have Highly Resilient.

vTv Therapeutics  (FRA:5VT0) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

vTv Therapeutics Tariff Resilience Score Related Terms

FRA:5VT0 vs SMNR, CNTB, ENLV: Tariff Resilience Score Comparison

For the Biotechnology subindustry, vTv Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Tariff Resilience Score falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
vTv Therapeutics (FRA:5VT0) has a Tariff Resilience Score of 8 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, vTv Therapeutics ranks #18 out of 1373 companies in the Biotechnology industry, placing it in the top 1.3%.
Is vTv Therapeutics' Tariff Resilience Score too high?
vTv Therapeutics' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. vTv Therapeutics' value of 8 is 100% above this industry median. Based on the distribution chart, vTv Therapeutics ranks #18 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Tariff Resilience Score compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #18 out of 1373 companies for Tariff Resilience Score. This places vTv Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. vTv Therapeutics' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Tariff Resilience Score of 8. The stock's GF Value™ is €6,725.03, compared to a current price of €30.20 — trading 99.6% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €30.20 is trading 99.6% below its estimated GF Value™ of €6,725.03.

Key valuation signals for FRA:5VT0:

  • Tariff Resilience Score: 8
  • GF Value™: €6,725.03 vs. price of €30.20 (99.6% below fair value)
  • GF Score™: 35/100
  • Industry Position: 100% above the Biotechnology median (#18 of 1373)

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.20
Price
€6,725.03
GF Value